# US 2026/0176650 A1 · T cells with increased expression of malic enzyme 1 and uses thereof in cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0176650 A1
- Document ID: US20260176650A1
- Status: Published application
- Kind: A1
- Application number: 19/125,409
- Filed: 2023-11-03
- Published: 2026-06-25
- Earliest claimed: 2022-11-04
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Haidong Dong; Joanina K. Gicobi
- Web page: https://patentgrep.com/patent/US20260176650A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12N 15/85: for animal cells
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/34: Antigenic peptides
- A61K 40/42: Cancer antigens
- A61K 40/4244: {Enzymes}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12Y 101/0104: Malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) (1.1.1.40)
- A61K 2239/57: Skin; melanoma
- A61K 2239/58: Prostate
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Methods and materials for increasing expression of malic enzyme 1 (ME1) in T cells are provided herein, as are compositions containing ME1 coding sequences or ME1 mRNA, and methods and materials for using T cells with increased ME1 levels to treat mammals having cancer.

## Claims

### Claim 1

A method for increasing a level of malic enzyme 1 (ME1) in a cell, said method comprising:
introducing into said cell a nucleic acid encoding ME1, and
incubating said cell such that said nucleic acid is expressed, thereby increasing the level of ME1 in said cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cell is a T cell.

### Claim at position 3

3-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the nucleic acid encoding ME1 comprises the nucleotide sequence set forth in SEQ ID NO:8, or having a nucleotide sequence with at least 90% identity to the nucleotide sequence set forth in SEQ ID NO:8.

### Claim 9

A method for treating a mammal, said method comprising administering to said mammal a composition comprising cells that comprise an exogenous nucleic acid encoding ME1, such that said cells have an elevated level of ME1.

### Claim 10 (depends on 9)

The method of claim 9, wherein said mammal is a human.

### Claim 11 (depends on 10)

The method of claim 10, wherein said human has cancer.

### Claim at position 8

12-13. (canceled)

### Claim 14 (depends on 9)

The method of claim 9, wherein are said cells are T cells.

### Claim at position 10

15-19. (canceled)

### Claim 20 (depends on 9)

The method of claim 9, wherein the nucleic acid encoding ME1 comprises the nucleotide sequence set forth in SEQ ID NO:8, or having a nucleotide sequence with at least 90% identity to the nucleotide sequence set forth in SEQ ID NO:8.

### Claim 21

A composition comprising PBMCs that comprise an exogenous nucleic acid encoding ME1.

### Claim at position 13

22-26. (canceled)

### Claim 27

A method for increasing a level of a polypeptide having malic enzyme 1 (ME1) activity in a cell, wherein said method comprises:
(a) introducing into said cell a nucleic acid encoding said polypeptide, and
(b) incubating said cell such that said nucleic acid is expressed, thereby increasing the level of said polypeptide in said cell.

### Claim at position 15

28-30. (canceled)

### Claim 31 (depends on 27)

The method of claim 27, wherein said cell is a T cell.

### Claim at position 17

32-34. (canceled)

### Claim 35

A method for treating a mammal, wherein said method comprises administering to said mammal a composition comprising cells comprising an exogenous nucleic acid that encodes a polypeptide having ME1 activity, wherein said cells have an elevated level of said polypeptide.

### Claim at position 19

36-38. (canceled)

### Claim 39 (depends on 35)

The method of claim 35, wherein said mammal is a human.

### Claim 40 (depends on 39)

The method of claim 39, wherein said human has cancer.

### Claim 41 (depends on 40)

The method of claim 40, wherein said cancer is lung cancer, breast cancer, prostate cancer, colorectal cancer, gastric cancer, pancreatic cancer, melanoma, sarcoma, or ovarian cancer.

### Claim 42

(canceled)

### Claim 43 (depends on 35)

The method of claim 35, wherein are said cells are T cells.

### Claim 44 (depends on 43)

The method of claim 43, wherein said T cells are CTLs.

### Claim 45 (depends on 44)

The method of claim 44, wherein said CTLs are CX3CR1+ CTLs.

### Claim 46 (depends on 43)

The method of claim 43, wherein said T cells are CAR-T cells or TCR-T cells.

### Claim 47 (depends on 35)

The method of claim 35, wherein said cells were obtained from said mammal and transfected with said nucleic acid.

### Claim 48

(canceled)
